Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...